资本风云|港股“BD之王”和铂医药,为何将前BD功臣告上法庭?

新浪财经
Yesterday

来源:创业最前线港股市场今年最风光的创新药公司之一,在受合作方与资本追捧的同时,正将从前的“功臣”告上法庭。9月初,有港股“BD(对外授权)之王”之称的和铂医药,与前高管徐伟豪的商业秘密官司进入密集推进阶段。和铂医药凭借其抗体技术平台产生的早期分子与全球药企达成广泛合作,仅2025年迄今就已宣布总额超过60亿美元的合作交易。而此案的被告方徐伟豪,正是公司过去几年BD合作的关键操盘手。如今,双方却因...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10